What Is Retatrutide and Should You Buy It From a Compounding Pharmacy?
Retatrutide is not FDA-approved. There is no commercially available version. What compounding pharmacies are selling under its name is not the same drug that produced a 28.7% average weight loss in Eli Lilly's Phase 3 trial.
The approved GLP-1 options — injectable and oral — are available right now at cash-pay prices significantly lower than a year ago, starting at $149/month. If you're trying to figure out what you'd actually pay, the pricing table is below.
GLP-1 Cash-Pay Pricing in 2026
Well Endocrinology · Updated May 2026
Every available option, current cash-pay prices, what's coming, and what to avoid.
| Medication | Type | Indication | FDA Status | Monthly Price |
|---|---|---|---|---|
| Wegovy (semaglutide) — pen | Injectable, weekly | Weight management + CV risk | Approved | New patients: $199/mo first 2 months (starter doses, through June 2026), then $349/mo · HD 7.2mg: $399/mo — NovoCare, CVS, Walgreens, retail pharmacies nationwide |
| Wegovy (semaglutide) — pill | Oral, daily | Weight management | Approved | 1.5mg: $149/mo · 4mg: $149/mo (through Aug 31 2026, then $199/mo) · Other doses: $199–$299/mo — NovoCare, CVS, retail pharmacies |
| Zepbound (tirzepatide) — vial or KwikPen | Injectable, weekly | Weight management + sleep apnea | Approved | 2.5mg: $299/mo · 5mg: $399/mo · 7.5–15mg: $449/mo (Self Pay Journey Program, refill within 45 days) — LillyDirect, Walgreens, Amazon Pharmacy, Kroger, Sam's Club, Walmart |
| Foundayo (orforglipron) — pill | Oral, daily | Weight management | Approved | Starter doses (0.8mg, 2.5mg): $149/mo · Mid doses (5.5mg, 9mg): $299/mo · Higher doses (14.5mg, 17.2mg): $299/mo with Self Pay Journey Program (refill within 45 days), otherwise $349/mo — LillyDirect, Amazon Pharmacy, retail pharmacies |
| Saxenda / Generic liraglutide | Injectable, daily | Weight management | Approved | Brand Saxenda: $1,300–$1,800/mo retail · Generic liraglutide (Teva, approved Aug 2025): from ~$370/mo with GoodRx — no manufacturer direct-pay program; daily injection |
| Generic semaglutide (Canada) — Dr. Reddy's / Apotex | Injectable, weekly | Type 2 diabetes (Canada only) | Not FDA approved | Health Canada approved April 28 / May 1, 2026. Not yet on shelves. Projected $60–$100 CAD/mo once available. Weight management indication not approved. |
| Retatrutide (compounded) | — | — | Not approved | Do not buy this |
Prices current as of May 2026. NovoCare introductory pricing ($199/mo) for new patients through June 2026, starter doses only. Zepbound and Foundayo Self Pay Journey Program pricing requires refill within 45 days; standard prices apply otherwise. Saxenda has no equivalent manufacturer direct-pay program — generic liraglutide (Teva) available from ~$370/mo with GoodRx at retail pharmacies. Canadian generic semaglutide not yet on shelves; pricing projected, not confirmed.
Wegovy Pill vs. Injection — Is the Oral GLP-1 as Effective?
Short answer: no, but it depends on what you're optimizing for.
Two oral GLP-1s reached approval in the last six months. The Wegovy pill (oral semaglutide, approved December 2025) must be taken on an empty stomach with a 30-minute wait before eating — every morning, no exceptions. In the OASIS 4 Phase 3 trial, it produced 13.6% mean weight loss at 64 weeks in the treatment-policy analysis, and 16.6% among patients who fully adhered to the protocol (Wharton et al., NEJM 2025).
Foundayo (orforglipron, approved April 1, 2026) is a small-molecule non-peptide compound — chemically different from semaglutide — and can be taken any time of day with no food or water restrictions. In the ATTAIN-1 trial, it produced approximately 11.1% mean weight loss at 72 weeks regardless of adherence, and 12.4% among completers (Eli Lilly ATTAIN program, 2026).
For comparison: injectable semaglutide (Wegovy) produces approximately 15% mean weight loss. Injectable tirzepatide (Zepbound) produces approximately 20–22%.
If you cannot or will not inject, the oral options are real and meaningful. If maximizing weight loss is the goal, the injectables remain the stronger choice. This is a decision that depends on your starting point, your metabolic history, and what you're actually willing to do consistently — which is why it warrants a clinical conversation, not a Google search.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist being developed by Eli Lilly. It activates GLP-1, GIP, and glucagon receptors simultaneously. Tirzepatide hits two. Semaglutide hits one. The addition of glucagon receptor activation drives additional energy expenditure beyond what dual or single agonists produce — which is reflected in the trial data.
In TRIUMPH-4, the first Phase 3 trial to report results (December 2025), participants on the 12mg dose lost an average of 28.7% of body weight at 68 weeks — approximately 71 pounds. The trial also showed significant reductions in knee pain, blood pressure, and non-HDL cholesterol. Seven additional Phase 3 readouts are expected in 2026. FDA and EMA submissions are planned after those results.
That 28.7% figure is the highest weight loss number we have seen from any drug in this class. I have been watching this drug for two years. If the remaining trials hold, it will be a meaningful addition to obesity medicine — likely available late 2026 at the earliest.
Is Compounded Retatrutide Safe?
No. And the legal picture is different from compounded semaglutide or tirzepatide.
The shortage exemption that briefly made compounded GLP-1s defensible required those specific drugs to be on the FDA drug shortage list. The FDA removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025. Enforcement deadlines for compounders passed by May 2025. As of mid-2025, mass compounding of both is no longer legally permissible under 503A or 503B pathways.
Retatrutide has never been on the shortage list. It has never been approved. There is no exemption. Compounders making it have no legal basis and no framework to produce it safely — no standardized dosing, no manufacturing oversight, and no safety data outside of controlled clinical trials where every vial and every dose was tracked.
The FDA logged more than 1,150 adverse events tied to compounded semaglutide and tirzepatide as of mid-2025, with roughly 10 deaths potentially connected. Those are reported numbers only — 503A pharmacies have no legal obligation to report adverse events to the FDA. The actual count is higher.
Compounded retatrutide carries all of that risk with none of the regulatory constraints that even partially governed the compounded semaglutide market. It is a different category of exposure.
How to Find a GLP-1 Prescriber in the Chicago Area
Deciding which GLP-1 is appropriate for your situation requires an actual clinical evaluation — your metabolic history, cardiovascular risk, A1c if applicable, how much weight loss you're trying to achieve, what medications you're already on, and what you're realistically going to do consistently.
Well Endocrinology is a direct-care endocrinology practice in Hinsdale, IL, serving patients across the Chicago western suburbs. I'm Dr. Sobia Sadiq — triple board-certified in Internal Medicine, Endocrinology, and Obesity Medicine, and prescribing GLP-1 medications for over a decade. No insurance. No referrals. New patient consults are 60 minutes. We look at the full metabolic picture, determine what you're actually a candidate for, and build a monitoring plan that makes sense for your situation.
If you want to book a consult, you can do that here:
If you're not ready to book but want clinical updates on retatrutide and the GLP-1 pipeline as Phase 3 data comes in, sign up for the newsletter below.
